Mutations that activate growth factor signaling often drive cancer growth. Many also arise in isolation, causing developmental growth disorders. PIK3CA, that encodes a catalytic subunit of phosphatidylinositol 3-kinase (PI3K), is a cardinal example of this paradigm. Recent exciting progress towards the key goal of cancer drug repurposing for PIK3CA-driven overgrowth is discussed.
Trial registration: ClinicalTrials.gov NCT04589650.
Keywords: CLOVES; PI3K; PIK3CA; PROS; alpelisib; overgrowth; phosphatidylinositol 3-kinase; sirolimus; trials.
Copyright © 2022 Elsevier Ltd. All rights reserved.